<DOC>
	<DOCNO>NCT01242787</DOCNO>
	<brief_summary>The purpose study investigate long-term safety antiviral activity optimal dos LB80380 additional 48 week treatment-naive patient chronic hepatitis B infection compare entecavir 0.5 mg .</brief_summary>
	<brief_title>Long-term Safety Efficacy Study LB80380 Treatment-naive Patients Chronic Hepatitis B</brief_title>
	<detailed_description>LB80380 , oral prodrug , promise candidate nucleotide analogue antiviral activity wild-type hepatitis B virus ( HBV ) . LB80380 undergo clinical development LG Life Sciences use treatment chronic HBV infection . This study extension study Phase IIb ( Protocol No . LG-BVCL007 ) , treatment period study 48-week 24-week follow-up period</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>The patient able participate expand study without interruption complete 48 week treatment LGBVCL007 study Coinfection hepatitis C D virus ( HCV HDV ) HIV Decompensated liver disease ALT &gt; 10 x ULN Creatinine clearance ( calculate cockcroftgault formula ) less 50 ml/min Alphafetoprotein ( AFP ) value great equal 50 ng/mL , followup ultrasonography perform prior baseline show finding indicative HCC Treatment immunomodulatory agent corticosteroid within 6 month prior study entry . Pregnancy breastfeed Patient currently abuse alcohol illicit drug Significant systemic illness liver disease Presence cause liver disease Plan liver transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>66 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Chronic hepatitis B</keyword>
	<keyword>LB80380</keyword>
	<keyword>treatment-naive</keyword>
	<keyword>entecavir</keyword>
	<keyword>Extension</keyword>
</DOC>